What do the data say about chemotherapy-induced peripheral neuropathy assessment and management?
Year: 2022
Type: editorial
Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) affects nearly 7 in 10 patients receiving neurotoxic chemotherapy treatment (e.g., taxanes, platinums, vinca alkaloids). The symptoms of CIPN include numbness (reduced sensation and proprioception), tingling, pain and/or weakness in the bilateral upper and lower extremities and may negatively affect physical function during and in the years following chemotherapy completion. Due to the lack of effective CIPN treatments, clinicians and patients are faced with the difficult decision of whether to stop chemotherapy early to decrease CIPN progression and preserve patients’ physical function but risk suboptimal tumor-treating chemotherapy dosages.
Authors: Grace Kanzawa-Lee, Robert Knoerl
Institution: University of Michigan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,980
OpenAlex ID: W4309892779